linjc16/ctgov huggingface dataset:
Effects of Yoga Training on Postural Stability

Study Overview
=================
Brief Summary
-----------------
Postural stability can be affected by multiple factors. Such as; body mass, inactivity, age and etc. This study was planned with the aim of investigating the effects of Yoga training on postural stability of males and females. Yoga is a treatment model for body flexibility, body awareness, and strength.

Detailed Description
-----------------
Postural stability can be affected by multiple factors. Such as; body mass, inactivity, age and etc. This study was planned with the aim of investigating the effects of Yoga training on postural stability of males and females. Yoga is a treatment model for body flexibility, body awareness, and strength.

Official Title
-----------------
Effects of Yoga Training on Postural Stability and Investigating the Gender-Related Responses

Conditions
-----------------
Gender, Postural; Defect, Physical Activity

Intervention / Treatment
-----------------
* Other: yoga treatment; flexibility, balance and strength exercises.


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Sedentary males and females want to participate Exclusion Criteria: have any disorders such as; neurologic, orthopedic, psychiatric or/and systemic.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 25 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: males<br>healthy, sedentary males | Other: yoga treatment; flexibility, balance and strength exercises.<br>* yoga treatment including flexibility exercises, balance exercises, and strength exercises.<br>|
| Experimental: females<br>healthy, sedentary females | Other: yoga treatment; flexibility, balance and strength exercises.<br>* yoga treatment including flexibility exercises, balance exercises, and strength exercises.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Postural stability score | Postural stability score is a composite score including the ability of standing upright position without swing. Individuals stands on a flat platform and perform stepping with possible least changes on their location. | at first minute, at the 2nd day, at the 15th day and at the30th day |
Bispectral Index to Guide Intubation in Pediatric Anesthesia

Study Overview
=================
Brief Summary
-----------------
This prospective study aimed to determine the minimal level of Bispectral index needed for quality laryngoscopy before ear, nose and throat surgery in children.

Detailed Description
-----------------
Children will received intra-rectal premedication based on midazolam 0.4mg Children will be monitored according to standard guidelines One blinded anesthesiologist will be in charge of anesthesia induction and the other one will be in charge of data collection (end tidal sevoflurane concentration, sevoflurane minimal alveolar concentration, bispectral index) and guidance of induction according to the predetermined bispectral index (up and down allocation)

Official Title
-----------------
Use of Bispectral Index to Guide Intubation During Sevoflurane Anesthesia in Children

Conditions
-----------------
Anesthesia

Intervention / Treatment
-----------------
* Drug: Sevoflurane


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: American Society Anesthesiology physical status classification system :1 or 2 scheduled ear, nose and throat surgery in a one day program oral intubation required Exclusion Criteria: parents refusal recent respiratory infection epilepsy suspected difficult intubation

Ages Eligible for Study
-----------------
Minimum Age: 2 Years
Maximum Age: 8 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: sevoflurane<br>induction of anesthesia using sevoflurane administered with facial mask at inspired concentration of 6% (in a mixture of oxygen and nitrous oxyde) intervention : titration of inspired sevoflurane concentration until targeted bispectral index | Drug: Sevoflurane<br>* After at least 4 minutes of stable inspired sevoflurane concentration, that concentration will be titrated to obtain a targeted bispectral index (BIS) level required for perform laryngoscopy. This level was initially set at 40, based on a preliminary study showing that such level of BIS was obtained at the laryngoscopy after common general anesthesia induction. For the next patients, BIS target was set according to a sequential allocation method (up and down).<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| laryngeal conditions of intubation | specific conditions will be assessed and scored : jaw relaxation, vocal cord position, cough at intubation | 5 minutes |
Diagnostic Accuracy of Human Transcriptional Activator(MYB) Expression by ELISA Technique Versus Immmunohistochemistry in Detecting Salivary Gland Carcinomas

Study Overview
=================
Brief Summary
-----------------
in this resarch we will use ELISA Technique to estimate Human Transcriptional Activator(MYB) Expression .compare it by Immmunohistochemistry analysis of MYB Expression in the malignant and benign salivary gland tumor

Official Title
-----------------
Diagnostic Accuracy of Human Transcriptional Activator(MYB) Expression by ELISA Technique Versus Immmunohistochemistry in Detecting Salivary Gland Carcinomas

Conditions
-----------------
Malignant Neoplasm of Salivary Gland, Benign Neoplasm of Salivary Gland

Intervention / Treatment
-----------------
* Device: enzyme linked immunosorbent assay (ELISA)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: . Patients with clinically evident salivary gland tumors; malignant tumors will be recruited in group I Benign tumors will be recruited in group II. Exclusion Criteria: Subjects taking any drugs inducing any changes that could affect the salivary glands. Pregnant females. Subjects having any allergies, infectious or autoimmune diseases. Subjects having any metabolic disorders that can be manifested with salivary gland swelling as diabetes mellitus.
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Group I<br>patients suffering from malignant salivary gland tumors. | Device: enzyme linked immunosorbent assay (ELISA)<br>* ELISA measure MYB in tissue biopsy in benign and malignant salivary gland tumors<br>|
| Group II<br>patients suffering from benign salivary gland tumors. | Device: enzyme linked immunosorbent assay (ELISA)<br>* ELISA measure MYB in tissue biopsy in benign and malignant salivary gland tumors<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Diagnostic Accuracy of Human Transcriptional Activator(MYB) Expression by ELISA Technique Versus Immmunohistochemistry in Detecting Salivary Gland Carcinomas | Diagnostic Accuracy of Human Transcriptional Activator(MYB) Expression by ELISA Technique Versus Immmunohistochemistry in Detecting Salivary Gland Carcinomas. | two years |
Phase II Efficacy Study of AZD6244 in Colorectal Cancer

Study Overview
=================
Brief Summary
-----------------
The purpose of the study is to assess if there is benefit when using AZD6244 in the treatment if metastatic colorectal cancer in comparison with another treatment called capecitabine. This study will also assess how safe and well tolerated AZD6244 is.

Official Title
-----------------
A Phase II, Open, Randomized Study to Assess the Efficacy and Safety of AZD6244 vs Capecitabine (Xeloda) in Patients With Colorectal Cancer Who Have Failed One or Two Prior Chemotherapeutic Regimens.

Conditions
-----------------
Metastatic Colorectal Cancer

Intervention / Treatment
-----------------
* Drug: AZD6244
* Drug: Capecitabine


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: colorectal cancer require treatment but have failed one or two previous chemotherapeutic regimens that must have included oxaliplatin and/or irinotecan have World Health Organisation (WHO) performance status 0-2 and life expectancy > 12 weeks Exclusion Criteria: previous therapy with EGFR inhibitor, MEK inhibitor or capecitabine any recent surgery, unhealed surgical incision or severe concomitant condition which makes it undesirable for the patient to participate in the study nausea and vomiting, chronic gastrointestinal disease or significant bowel resection that would preclude adequate absorption

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: 1<br>Xeloda | Drug: Capecitabine<br>* oral tablet<br>* Other names: Xeloda;|
| Experimental: 2<br>AZD6244 | Drug: AZD6244<br>* oral vial<br>* Other names: ARRY-142886;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Progression event count |  | assessed after each visit | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| safety and tolerability |  | assessed at each visit | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
colorectal cancer, AZD6244
Vitamin A, Its Receptors and Asthma

Study Overview
=================
Brief Summary
-----------------
We wish to understand the association of Vitamin A serum levels and Vitamin A receptor number and responsiveness in asthmatics. We believe that Vitamin A receptors may be less prevalent in asthmatics and their responsiveness decreased.

Detailed Description
-----------------
We wish to define the association of asthma, vitamin A serum levels and vitamin A receptor number and responsiveness on circulating mononuclear cells. Asthma is a complex, heterogenous and often debilitating and potentially deadly disease. The causes for asthma are many, with susceptibility and resistance to treatment is poorly understood. Ultimately, looking at this disease from another angle such as the role of Vitamin A and/or receptors can help us learn more about the pathophysiology and treatment of asthma.

Official Title
-----------------
Vitamin A, Its Receptors and Asthma: Vitamin A Levels in Serum and Expression and Responsiveness of Vitamin A Receptors in Circulating Mononuclear Cells of Asthmatics

Conditions
-----------------
Asthma

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with previously diagnosed asthma on inhaled corticosteroids, systemic steroids and/or long acting beta agonist (for a period of 6 mo to 5 years) Age 18-64 Male or female Exclusion Criteria: Children under age 18 Adults 65 or older Patients with COPD

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 64 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| 1<br> | |
| 2<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Retinol levels in blood, flow cytometric study of the RXRRAR receptors before and after addition of ATRA, 9-cis-RA and steroid |  | 2-4 weeks after blood sample drawn | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
asthma, retinol, cis-retinoic acid
Local Fields Potentials Recorded From Deep Brain Stimulating Electrodes

Study Overview
=================
Brief Summary
-----------------
Deep Brain Stimulation (DBS) is an FDA approved, and widely used method for treating the motor symptoms of Parkinson's Disease (PD), Essential Tremor (ET) and Dystonia. Over 100,000 patients worldwide have now been implanted with DBS devices. The DBS target regions in the brain are the Subthalamic nucleus (STN), the Internal Segment of Globus Pallidus (GPi), or the Ventral Intermediate Nucleus of the Thalamus (VIM). In order to place the DBS electrode in the target location, a combination of two 3D imaging techniques; 3D MRI and CT, are used. Data are also collected from individual nerve cells to help find the best location for the DBS electrode in each patient. This electrode recording takes place during the standard surgical implantation of the DBS electrode, and is part of the standard clinical technique. The investigators plan to collect additional data from populations of neurons during the DBS surgery in an effort to further improve the placement of the DBS electrode. These Local Field Potentials, LFPs, represent the activity of the collection of neurons surrounding the tip of the electrode, and will be measured during surgery along the path used for the placement of the DBS electrode. The goal of this project is to determine whether this additional data from surrounding neurons will help with optimal placement of the DBS electrode.

Official Title
-----------------
Local Field Potentials Recorded From Deep Brain Stimulating Electrodes Implanted for the Treatment of Parkinson's Disease, Essential Tremor or Dystonia

Conditions
-----------------
Parkinson's Disease, Essential Tremor, Dystonia

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Subjects included in this study will be those who are planning to undergo DBS surgery because of their underlying idiopathic Parkinson's disease, Essential Tremor, or Dystonia--all FDA-approved indications for the implantation of DBS devices. Exclusion Criteria: Subjects with the most advanced symptoms of PD (stage V in the Hoehn and Yahr rating scale). Subjects who are not planning to undergo DBS surgery. Subjects not candidates for DBS surgery based on clinical criteria.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Recording and evaluating LFPs from DBS electrodes | Recording and evaluating LFPs from DBS electrodes in patients with Parkinson's Disease, Essential Tremor or Dystonia | at baseline | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Deep Brain Stimulation, Local Field Potential, Subthalamic Nucleus
Expanded Access of Fostamatinib in Patients With Persistent or Chronic Relapsing/Refractory ITP

Study Overview
=================
Brief Summary
-----------------
C-935788-055 is an open-label, multi-center, expanded access (EAP) study.

Detailed Description
-----------------
The purpose of the program is to provide Fostamatinib in an Expanded Access setting to subjects who meet the selection criteria.

Official Title
-----------------
Expanded Access (Compassionate Use) of Fostamatinib in Patients With Persistent or Chronic Relapsing/Refractory Immune Thrombocytopenic Purpura (ITP)

Conditions
-----------------
Immune Thrombocytopenic Purpura

Intervention / Treatment
-----------------
* Drug: Fostamatinib disodium 100 mg
* Drug: Fostamatinib disodium 150 mg


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Adult patient with chronic or persistent ITP. Must have failed or are unable to receive standard of care treatments for ITP. Must have at least two platelet counts < 30,000/µL during the last 2 months prior to screen date. Exclusion Criteria: ITP associated with lymphoma, chronic lymphocytic leukemia, transplant, or thrombocytopenia associated with myeloid dysplasia. Subject has uncontrolled or poorly controlled hypertension. Any of the following laboratory abnormalities: neutrophil count of < 1,500/µL, or transaminase levels (ALT, AST) > 1.5x ULN, total bilirubin > 2.0 mg/dL. Active HBV or HCV infection. Current or recent enrollment in an investigational drug or device study.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Fostamatinib disodium 100 mg|Fostamatinib Disodium tablet 100 mg PO bid (morning and evening)|
|Drug: Fostamatinib disodium 150 mg|Fostamatinib Disodium tablet 150 mg PO bid (morning and evening)|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
ITP, Immune Thrombocytopenia
Flourish™ Pediatric Esophageal Atresia

Study Overview
=================
Brief Summary
-----------------
This study is continued evaluation of the safety and probable benefit of the Flourish Pediatric Esophageal Atresia device through the Humanitarian Device Exemption (HDE) pathway.

Official Title
-----------------
Flourish Pediatric Esophageal Atresia Device Post-Approval Study (Flourish)

Conditions
-----------------
Esophageal Atresia, Digestive System Abnormalities, Esophageal Disorders Congenital

Intervention / Treatment
-----------------
* Device: Flourish Pediatric Esphogeal Atresia device


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criterion: Patient treated for esophageal atresia with Flourish device starting May 12, 2017

Ages Eligible for Study
-----------------
Maximum Age: 12 Months

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Flourish device<br>The Flourish Pediatric Esophageal Atresia device is indicated for use in lengthening atretic esophageal ends and creating an anastomosis with a non-surgical procedure in pediatric patients. | Device: Flourish Pediatric Esphogeal Atresia device<br>* The Flourish Pediatric Esophageal Atresia device consists of an esophageal catheter and a gastric catheter. Both catheters are equipped with an inner magnet catheter. When the esophageal and gastric catheters are aligned tip to tip, the magnets attract.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Rate of Adverse Events | Adverse Events include: stricture at the anastomotic site leading to the need for dilation or surgery and peri-anastomotic leaks | 2 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Esophageal, Atresia, Congential
QOLBET Quality Of Life in Patients With Early Relapsing-remitting Multiple Sclerosis Treated With BETaferon® in Korea

Study Overview
=================
Brief Summary
-----------------
This study is to describe the quality of life of Korean patients with early relapsing-remitting multiple sclerosis during the initial 1 year of treatment with Betaferon with several validated questionnaires.

Official Title
-----------------
QOLBET Quality Of Life in Patients With Early Relapsing-remitting Multiple Sclerosis Treated With BETaferon® in Korea

Conditions
-----------------
Multiple Sclerosis, Relapsing-Remitting

Intervention / Treatment
-----------------
* Drug: Interferon beta 1-b (Betaferon/Betaseron, BAY86-5046)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Relapsing-remitting MS (RRMS) patients within the first two years after diagnosis according to Poser or McDonald criteria, starting Betaferon treatment, including patients switching from other DMDs Patients who signed informed consent form Exclusion Criteria: Age lower than 18

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Group 1<br> | Drug: Interferon beta 1-b (Betaferon/Betaseron, BAY86-5046)<br>* Patients receiving Betaferon according to routine clinical practice<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Quality of life evaluated by several validated questionnaire |  | Baseline, 3, 6, 9, 12 months (+/- 1 month) | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Information about safety of Betaferon in routine clinical use |  | Baseline, 3, 6, 9, 12 months (+/- 1 month) | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Multiple Sclerosis,, Relapsing-Remitting,, Interferon beta-1b,, Quality of life